Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Katie Groves, Arseniy Lavrov et al.|The Lancet Neurology|2021Cited by 260
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersenValeria Sansone, Giorgia Coratti, Maria Carmela Pera et al.|European Journal of Neurology|2020Cited by 19
Predominant distal muscle involvement in spinal muscular atrophyClaudia Brogna, Eugenio Mercuri, Lara Cristiano et al.|Neuromuscular Disorders|2019Cited by 4
Revised North Star ambulatory assessment for young boys with Duchenne muscular dystrophyEugenio Mercuri, Marika Pane, Giorgia Coratti et al.|Neuromuscular Disorders|2016Cited by 3
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational studyEugenio Mercuri, Marika Pane, Simona Lucibello et al.|Neuromuscular Disorders|2019Cited by 0